New RSV shield for infants: Real-World study launches
NCT ID NCT07109297
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how safe and effective nirsevimab is at preventing severe RSV in babies and young children. About 110 infants and toddlers up to 24 months old will receive the medicine as part of their regular care. Researchers will track side effects and how many children get sick with RSV needing medical attention.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RSV IMMUNIZATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Investigational Site Number : 3560001
New Delhi, 110060, India
-
Investigational Site Number : 3560002
Bengaluru, 560011, India
-
Investigational Site Number : 3560003
Kolkata, 700017, India
-
Investigational Site Number : 3560004
Pune, 411007, India
-
Investigational Site Number : 3560006
Vizianagaram, 535003, India
-
Investigational Site Number : 3560007
Nagpur, 441108, India
-
Investigational Site Number : 3560008
Jaipur, 302007, India
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- RSV vaccine may shield babies born to mothers with HIV
- Czech RSV shot study: will parents protect their babies?
- Queensland study reveals why parents say yes or no to RSV shot for babies
- New RSV vaccine for infants shows promise in major trial
- Can the RSV vaccine protect the most vulnerable? new study aims to find out
- Double defense against RSV: could Mom's vaccine plus Baby's shot be the key?